BA
Boeing
-- 180.720 TSLA
Tesla
-- 431.660 NVDA
NVIDIA
-- 137.010 RGTI
Rigetti Computing
-- 17.0800 PLTR
Palantir
-- 79.080 
NEWS
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
BioVie Inc. (NASDAQ: BIVI) presented clinical data on bezisterim at the 11th Aging Research and Drug Discovery Meeting, revealing its potential to modulate inflammation and the biological aging process. Key findings include:
1. Patients treated with bezisterim experienced a 2-4 year age deceleration advantage compared to placebo.
2. Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages.
3. The drug was associated with a 1.5 to 2.3 'fold enrichment' on gene control for hundreds of genes in pathways linked to neurodegenerative disorders and biological processes.
These results suggest bezisterim's potential to impact various age-related diseases and inflammation-related conditions.
1. Patients treated with bezisterim experienced a 2-4 year age deceleration advantage compared to placebo.
2. Bezisterim modulated DNA methylation of proinflammatory genes and appeared to promote the transition of M1 proinflammatory to M2 anti-inflammatory macrophages.
3. The drug was associated with a 1.5 to 2.3 'fold enrichment' on gene control for hundreds of genes in pathways linked to neurodegenerative disorders and biological processes.
These results suggest bezisterim's potential to impact various age-related diseases and inflammation-related conditions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment